BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32901086)

  • 21. Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer.
    Vázquez SM; Endepols H; Fischer T; Tawadros SG; Hohberg M; Zimmermanns B; Dietlein F; Neumaier B; Drzezga A; Dietlein M; Schomäcker K
    Mol Imaging Biol; 2022 Feb; 24(1):115-125. PubMed ID: 34370181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ImmunoPET imaging of human CD8
    Zhao H; Wang C; Yang Y; Sun Y; Wei W; Wang C; Wan L; Zhu C; Li L; Huang G; Liu J
    J Nanobiotechnology; 2021 Feb; 19(1):42. PubMed ID: 33563286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spatiotemporal PET Imaging Reveals Differences in CAR-T Tumor Retention in Triple-Negative Breast Cancer Models.
    Volpe A; Lang C; Lim L; Man F; Kurtys E; Ashmore-Harris C; Johnson P; Skourti E; de Rosales RTM; Fruhwirth GO
    Mol Ther; 2020 Oct; 28(10):2271-2285. PubMed ID: 32645298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiolabelling of the octadentate chelators DFO* and oxoDFO* with zirconium-89 and gallium-68.
    Brandt M; Cowell J; Aulsebrook ML; Gasser G; Mindt TL
    J Biol Inorg Chem; 2020 Aug; 25(5):789-796. PubMed ID: 32661784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and characterisation of zirconium complexes for cell tracking with Zr-89 by positron emission tomography.
    Ferris TJ; Charoenphun P; Meszaros LK; Mullen GE; Blower PJ; Went MJ
    Dalton Trans; 2014 Oct; 43(39):14851-7. PubMed ID: 25164373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The next generation of positron emission tomography radiopharmaceuticals in oncology.
    Rice SL; Roney CA; Daumar P; Lewis JS
    Semin Nucl Med; 2011 Jul; 41(4):265-82. PubMed ID: 21624561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
    Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [
    Zhang P; Zhao Z; Zhang L; Wu W; Xu Y; Pan D; Wang F; Yang M
    Nucl Med Biol; 2019; 74-75():19-24. PubMed ID: 31450071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
    Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA
    J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression.
    Li ZB; Chen K; Chen X
    Eur J Nucl Med Mol Imaging; 2008 Jun; 35(6):1100-8. PubMed ID: 18204838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiolabelling of Polyclonally Expanded Human Regulatory T Cells (Treg) with
    Jacob J; Volpe A; Peng Q; Lechler RI; Smyth LA; Lombardi G; Fruhwirth GO
    Molecules; 2023 Feb; 28(3):. PubMed ID: 36771148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD4
    Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
    Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PET imaging of a
    Xu Y; Wang L; Pan D; Yu C; Mi B; Huang Q; Sheng J; Yan J; Wang X; Yang R; Yang M
    Br J Radiol; 2019 Dec; 92(1104):20190425. PubMed ID: 31593482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclotron Production of PET Radiometals in Liquid Targets: Aspects and Prospects.
    Pandey MK; DeGrado TR
    Curr Radiopharm; 2021; 14(4):325-339. PubMed ID: 32867656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a New Folate-Derived Ga-68-Based PET Imaging Agent.
    Brand C; Longo VA; Groaning M; Weber WA; Reiner T
    Mol Imaging Biol; 2017 Oct; 19(5):754-761. PubMed ID: 28194631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
    Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
    J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy.
    Tavaré R; Escuin-Ordinas H; Mok S; McCracken MN; Zettlitz KA; Salazar FB; Witte ON; Ribas A; Wu AM
    Cancer Res; 2016 Jan; 76(1):73-82. PubMed ID: 26573799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, Synthesis, and Biological Evaluation of
    Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z
    Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo preclinical evaluation of the new
    Trencsényi G; Kis A; Szabó JP; Ráti Á; Csige K; Fenyvesi É; Szente L; Malanga M; Méhes G; Emri M; Kertész I; Vecsernyés M; Fenyvesi F; Hajdu I
    Int J Pharm; 2020 Feb; 576():118954. PubMed ID: 31935470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Translation and First In-Human Use of [
    Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
    Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.